Clinical Trials Logo

Acute Myeloid Leukemia Recurrent clinical trials

View clinical trials related to Acute Myeloid Leukemia Recurrent.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06152809 Active, not recruiting - Leukemia Clinical Trials

CIML NK Cells With Venetoclax for AML

Start date: February 20, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML). Names of the study therapies involved in this study are: - Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion - CIML NK (a cellular therapy) - IL-2 (a recombinant, human glycoprotein) - Venetoclax (a selective inhibitor of BCL-2 protein)